– In June 2024, the Company announced groundbreaking pivotal study data for PRGN-2012 gene therapy at the 2024 ASCO annual meeting in which more than half of RRP patients achieved Complete Response – – In July 2024, the Company appointed Phil Tennant as Chief Commercial Officer to spearhead potential PRGN-2012 commercial launch – – In August 2024, the Company announced a strategic reprioritization of its pipeline to focus on advancement of its lead program, PRGN-2012 in RRP – – PRGN-2012 rolling BLA submiss ...

GERMANTOWN, Md., Aug. 9, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release second quarter and first half 2024 financial results and provide business updates on Wednesday, August 14, 2024. The Company will host a conference call that day at 4:30 PM ET to discuss financial results and provide a general business update. The conference cal ...

GERMANTOWN, Md., Aug. 7, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 35,294,118 shares of its common stock at a public offering price of $0.85 per share. Precigen has also granted the underwriters a 30-day option to purchase up to an additional 5,294,117 shares of its common stock. Gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Precigen, Inc. (PGEN) reports results for the quarter ended June 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock ...

GERMANTOWN, Md., July 23, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the appointment of Phil Tennant as the Company's chief commercial officer. Mr. Tennant will be responsible for commercial strategy and execution across US and global markets. His initial focus will be on driving commercial readiness activities for the potential launch of the first- and ...

– Phase 1/2 pivotal study met the primary safety and efficacy endpoints – – 51% (18 out of 35) of patients achieved Complete Response, requiring no surgeries after treatment with PRGN-2012; complete responses have been durable beyond 12 months with median duration of follow up of 20 months as of data cutoff – – 86% of patients (30 out of 35) had a decrease in surgical interventions in the year after PRGN-2012 treatment compared to the year prior to treatment; RRP surgeries reduced from a median of 4 pre-tre ...

GERMANTOWN, Md., May 23, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company will host a webcast on June 3, 2024 at 6:00 PM CT/7:00 PM ET following the late-breaking oral presentation of results from the pivotal study of PRGN-2012 for the treatment of recurrent respiratory papillomatosis (RRP) at the 2024 American Society of Clinical Oncology (A ...

Precigen, Inc. (PGEN) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.10 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of -11.11%. A quarter ago, it was expected that this company would post a loss of $0.08 per share when it actually produced a loss of $0.09, delivering a surprise of -12.50%. Over the last four quarters, the company has surp ...

Washington, D.C. 20549 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 (Exact name of registrant as specified in its charter) Virginia 26-0084895 (State or other jurisdiction of incorporation or organization) 20374 Seneca Meadows Parkway Germantown, Mar ...

Financial Performance - Total revenues decreased by $0.8 million, or 43%, compared to the three months ended March 31, 2023[14]. - Total revenues for Q1 2024 were $1,065,000, a decrease of 42.3% compared to $1,851,000 in Q1 2023[29]. - Product revenues decreased to $138,000 from $324,000, while service revenues fell to $919,000 from $1,527,000[29]. - Operating loss for Q1 2024 was $24,410,000, compared to a loss of $23,478,000 in Q1 2023[29]. - Net loss was $23.7 million, or $(0.10) per basic and diluted share, compared to a net loss of $22.7 million, or $(0.10) per basic and diluted share, in the prior year[14]. - Net loss for Q1 2024 was $23,738,000, consistent with a net loss of $22,734,000 in Q1 2023[29]. - The company reported a net loss per share of $0.10 for both Q1 2024 and Q1 2023[29]. Research and Development - Research and development expenses increased by $2.1 million, or 17%, compared to the same period in 2023[12]. - Research and development expenses increased to $14,249,000, up from $12,163,000 in the same period last year[29]. - 50% of patients in the Phase 1 portion of the PRGN-2012 study achieved Complete Response, defined as no surgeries needed during the 12-month period following treatment[6]. - 83% of patients had a reduction in RRP surgeries in the 12-month period after PRGN-2012 treatment compared to the 12 months pre-treatment[7]. - The FDA confirmed that the ongoing Phase 1/2 study of PRGN-2012 will serve as pivotal, eliminating the need for additional randomized trials for BLA submission[9]. - Precigen is advancing its UltraCAR-T library approach to enhance personalized cell therapy for cancer patients[21]. Cash and Assets - Cash, cash equivalents, and short-term investments totaled $44.8 million as of March 31, 2024[11]. - Cash and cash equivalents rose to $17,478,000 as of March 31, 2024, compared to $7,578,000 at the end of 2023[27]. - Total assets decreased to $134,847,000 from $151,043,000 at the end of 2023[27]. - Total liabilities increased to $37,828,000 from $32,545,000 at the end of 2023[27]. Corporate Initiatives - The company plans to co-sponsor the inaugural RRP Awareness Day on June 11, 2024, to raise awareness about recurrent respiratory papillomatosis[5]. - PRGN-2012 rolling BLA submission is anticipated in the second half of 2024, with commercial readiness activities underway for a potential launch in 2025[5]. Operating Expenses - SG&A costs decreased by $1.5 million, or 13%, compared to the same period in 2023[13].